Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

Florence Lerebours (1) , Marina Pulido (2) , Emmanuelle Fourme (3) , Marc Debled (4) , Véronique Bécette (5) , Hervé Bonnefoi (6) , Sofia Rivera (7) , Gaetan Macgrogan (6) , Marie-Ange Mouret-Reynier (8, 9) , Christine Tunon de Lara (10) , Jean-Yves Pierga (11) , Christel Breton-Callu , Laurence Venat-Bouvet (12) , Simone Mathoulin-Pelissier (13, 14) , Thibault de La Motte Rouge (15) , Florence Dalenc (16) , Brigitte Sigal (17) , Thomas Bachelot (18) , Jérôme Lemonnier (19) , Nathalie Quenel-Tueux

1 CRLCC René Huguenin - CRLCC René Huguenin
2 CIC Bordeaux
3 Institut National de Veille Sanitaire
4 Service d'Oncologie Médicale
5 Hôpital René Huguenin [Saint-Cloud]
6 VINCO - Validation et identification de nouvelles cibles en oncologie
7 RaMo-IT - Radiothérapie Moléculaire et Innovation Thérapeutique
8 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
9 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
10 Service de Chirurgie
11 Service d'Oncologie Médicale
12 Service d'Oncologie médicale [CHU Limoges]
13 Plateforme de génétique moléculaire des cancers d'Aquitaine
14 BPH - Bordeaux population health
15 CRLCC - CRLCC Eugène Marquis
16 Institut Claudius Regaud
17 Institut Curie [Paris]
18 Oncogénèse et progression tumorale
19 UNICANCER [Paris]

Few data are available on survival and predictive factors in early breast cancer (BC) patients treated with neoadjuvant endocrine therapy (NET).

Domaines: Sciences du Vivant [q-bio]; Cancer

Florence Lerebours, Marina Pulido, Emmanuelle Fourme, Marc Debled, Véronique Bécette, et al.. Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials. British Journal of Cancer, 2020, 122 (6), pp.759-765. ⟨10.1038/s41416-020-0733-x⟩. ⟨hal-02888491⟩